Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension

被引：0
|
作者：
Siegel, C. [1 ]
Danese, S. [2 ,3 ]
Rubin, D. T. [4 ]
Sabino, J. [5 ]
Long, M. D. [6 ]
Cross, R. K. [7 ]
Armuzzi, A. [8 ,9 ]
Blumenstein, I. [10 ]
Kobayashi, T. [11 ]
Lama, S. [12 ]
Charles, L. [12 ]
Cetin, V. [12 ]
Petersen, A. [12 ]
Wu, H. [12 ]
Wang, D. [13 ]
Jain, A. [12 ]
D'Haens, G. [14 ]
机构：
[1] Dartmouth Hitchcock Clin, Gastroenterol, Lebanon, NH USA
[2] IRCCS Osped San Raffaele, Gastroenterol & Endoscopy, Milan, Italy
[3] Univ Vita Salute San Raffaele, Gastroenterol & Endoscopy, Milan, Italy
[4] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Inflammatory Bowel Dis, Chicago, IL USA
[5] Univ Hosp Leuven, Gastroenterol, Dept Gastroenterol, Leuven, Belgium
[6] Univ N Carolina, Chapel Hill, NC USA
[7] Univ Maryland, Sch Med, Gastroenterol & Hepatol, Baltimore, MD 21201 USA
[8] IRCCS Humanitas Res Hosp Rozzano, Inflammatory Bowel Dis, IBD Ctr, Milan, Italy
[9] Humanitas Univ Pieve Emanuele, Dept Biomed Sci, Milan, Italy
[10] Goethe Univ Hosp, Inflammatory Bowel Dis, Frankfurt, Germany
[11] Kitasato Univ, Gastroenterol, Kitasato Inst Hosp, Tokyo, Japan
[12] Bristol Myers Squibb KK, Princeton, NJ USA
[13] Bristol Myers Squibb KK, Tokyo, Japan
[14] Amsterdam Univ Med Ctr, Gastroenterol & Hepatol, Amsterdam, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP16
引用
收藏
页码：I100 / I101
页数：2
相关论文
共 50 条
  • [41] A multicentre open-label study assessing pharmacokinetics, efficacy, and safety of subcutaneous golimumab in paediatric patients with moderately to severely active ulcerative colitis
    Turner, D.
    Veereman, G.
    Hyams, J.
    Griffiths, A.
    Chan, D.
    Adedokun, O. J.
    Damaraju, L.
    Strauss, R.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S364 - S365
  • [42] Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen
    Strauss, Rick
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    Tarabar, Dino
    GASTROENTEROLOGY, 2016, 150 (04) : S776 - S777
  • [43] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [44] Maintenance of Remission With Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis From an Open-Label, Long-Term Extension Study
    Colombel, Jean-Frederic
    Reinisch, Walter
    Osterman, Mark T.
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Zhang, Haiying
    Lawendy, Nervin
    Friedman, Gary S.
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S389 - S390
  • [45] Maintenance of Remission with Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis from an Open-Label, Long-Term Extension Study
    Jean-Frederic, Colombel
    Walter, Reinisch
    Mark, Osterman T.
    Andrew, Thorpe J.
    Chudy, Nduaka, I
    Zhang Haiying
    Nervin, Lawendy
    Gary, Friedman S.
    Su Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S4 - S4
  • [46] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
    Lichtenstein, G. R.
    Loftus, E. V., Jr.
    Wei, S. C.
    Damiao, A. O.
    Judd, D.
    Lawendy, N.
    Chan, G.
    Zhang, H.
    Wang, W.
    Thorpe, A. J.
    Bloom, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101
  • [47] Interim Analysis of an Open-Label Extension Study to Examine the Long-Term Safety and Tolerability of Pimavanserin in the Treatment of PD Psychosis
    Mills, R.
    Bahr, D.
    Williams, H.
    Peters, P.
    Isaacson, S.
    MOVEMENT DISORDERS, 2010, 25 : S674 - S674
  • [48] Laboratory Parameters Related to Monitoring in Patients With Ulcerative Colitis Treated With Tofacitinib for up to 3 Years in the OCTAVE Open-Label, Long-Term Extension Study
    Melmed, Gil Y.
    Chang, Shannon
    Kulisek, Nicole
    Fan, Haiyun
    Lawendy, Nervin
    Maller, Eric
    Soonasra, Arif
    Irving, Peter M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S431 - S431
  • [49] CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH
    Schreiber, Stefan
    Armuzzi, Alessandro
    Dignass, Axel
    Marta, Cecilia
    Petersen, AnnKatrin
    Huang, Vivian
    Sandborn, William J.
    GASTROENTEROLOGY, 2021, 160 (06) : S83 - S83
  • [50] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: Open-Label, Long-term Extension Study
    Lichtenstein, Gary R.
    Loftus, Edward V., Jr.
    Bloom, Stuart
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S395 - S395
12345